It is Hematopoeitic Growth Factor. It is a glycoprotein. It is usually made in the kidney.
Recombinant DNA technology is done to obtain human erythropoietin.
Mechanism of action:
It activates the multiplication (proliferation) and development of specialized functions (differentiation) of red blood cells by its interaction with particular erythropoietin receptors on the originators of red cells in the bone marrow.
It is used for the treatment of patients with end stage renal failure, significant anemic conditions caused by human immunodeficiency virus and anemia in patients of cancer.
It may cause hypertension and allergic conditions. Thrombotic complications may also develop. Minimum effective dose must not exceed 12g/dL of hemoglobin concentration. As more than 12g/dL of concentration can cause considerable life threatening effects on the heart and finally can lead to death.